January 13, 2021 – Vancouver, British Columbia, – Redfund Capital Corp. (CSE: LOAN) (Frankfurt:O3X4) (OTC QB: PNNRF) (Redfund or the “Company”) announces that it has partnered with Clarion Holdings of Eugene, Oregon to open one of the first psilocybin consulting incubators in the area.
Our team has assembled a formidable group of analysts consisting of homeopathic doctors, psychiatrists, cultivators and processors. Clarion Holdings has licenses in both cannabis and hemp, and we will partner together in our submission to be one of the first psilocybin applications in the state. As well, the firm will apply to become a white label processor of approved products. Oregon is only in the preliminary stage of organizing a board of advisors representing the passed initiative but being first and ready is important.
In November 2020 Oregon became the first state in the nation to legalize psilocybin in therapeutic settings. Measure 109 passed with 56% of the vote and it will be at least two years before psilocybin therapy is available in a therapeutic setting. Currently, there are no such policies in place anywhere else in the U.S.; nonetheless, there is a growing national movement to decriminalize psilocybin plus a wide range of entheogenic substances, including ayahuasca and ibogaine. Activists and health professionals in Washington State are pursuing legal psilocybin initiatives as well but the Right to Try mushroom is still in its infancy.
“This is the beginning of the two-year process to ensure that Oregon creates a safe, effective and equitable psilocybin therapy program that effectively addresses the patients who are suffering from depression and anxiety. Giving adults access to so-called magic mushrooms in a clinical setting is a major step forward to understand how mental illness can deprive people of a safe and healthy lifestyle. Global wellness strategies is our focus and we are fortunate to be involved in what will be the ground-breaking applications to help mental fitness,” said Meris Kott, CEO.
The Company also announces that it has issued 416,666 restricted common shares to an officer of the Company for compensation for services. The shares were issued at a deemed price of $0.06 per share.
About Redfund Capital Corp.
Redfund partners with first mover, high growth companies, and provides them with access to capital, resources, and infrastructure. The present focus of the merchant bank is on global wellness, hemp and CBD-related, healthcare-related target companies.
For further information please visit www.redfundcapital.com
For more information on Redfund Capital Corp. contact:
Meris Kott CEO
604.484.0355 or email@example.com
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.